Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

The value-for-money assessment and funding arrangements for high-priced drugs in an era of uncertainty: a comparative analysis of national health technology assessment agencies in South Korea, England, Australia, and Canada.

  • Authors : Hong J; Department of Healthcare Management, Gachon University, Seongnam-Si, Gyeonggi-Do, Republic of Korea.; Bae EY

Subjects: Technology Assessment, Biomedical* ; Cost-Benefit Analysis*; Republic of Korea

  • Source: BMC health services research [BMC Health Serv Res] 2025 Jan 14; Vol. 25 (1), pp. 74. Date of Electronic Publication: 2025 Jan 14.Publisher: BioMed Central Country of Publication: England NLM ID: 101088677 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6963

تفاصيل العنوان

×
Academic Journal

Cost, Cost-effectiveness and Survival Impact Assessment for A Better Management of Colorectal Cancer Patients: A Single Centre Comprehensive Analysis.

  • Authors : Gana AI; Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. . .; Bica C

Subjects: Cost-Benefit Analysis* ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/therapy ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/economics

  • Source: Journal of gastrointestinal and liver diseases : JGLD [J Gastrointestin Liver Dis] 2024 Dec 28; Vol. 33 (4), pp. 496-502. Date of Electronic Publication: 2024 Dec 28.Publisher:

تفاصيل العنوان

×
Academic Journal

Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States.

Subjects: Psoriasis*/Psoriasis*/Psoriasis*/drug therapy ; Psoriasis*/Psoriasis*/Psoriasis*/economics ; Thalidomide*/Thalidomide*/Thalidomide*/analogs & derivatives

  • Source: The Journal of dermatological treatment [J Dermatolog Treat] 2024 Dec; Vol. 35 (1), pp. 2366503. Date of Electronic Publication: 2024 Jun 24.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

×
Academic Journal

New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.

  • Authors : Stewart DJ; Division of Medical Oncology, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.; Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/economics ; Cost-Benefit Analysis*/Cost-Benefit Analysis*/Cost-Benefit Analysis*/methods

  • Source: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Apr 28; Vol. 31 (5), pp. 2453-2480. Date of Electronic Publication: 2024 Apr 28.Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729

تفاصيل العنوان

×
Academic Journal

Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.

  • Authors : Aungsumart S; Neuroimmunology Unit, Department of Neurology, Prasat Neurological Institute, Bangkok, Thailand.; Apiwattanakul M

Subjects: Cost-Benefit Analysis* ; Drug Costs*; Mycophenolic Acid/Mycophenolic Acid/Mycophenolic Acid/*economics

  • Source: PloS one [PLoS One] 2020 Feb 12; Vol. 15 (2), pp. e0229028. Date of Electronic Publication: 2020 Feb 12 (Print Publication: 2020).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

×
Academic Journal

Difficulties arising in reimbursement recommendations on new medicines due to inadequate reporting of population adjustment indirect comparison methods.

  • Authors : Holmes EM; Dundee Epidemiology and Statistics Unit, University of Dundee, Dundee, UK.; Scottish Medicines Consortium, Health Improvement Scotland, Glasgow, UK.

Subjects: Cost-Benefit Analysis* ; Drug Costs* ; Reimbursement Mechanisms*

  • Source: Research synthesis methods [Res Synth Methods] 2019 Dec; Vol. 10 (4), pp. 615-617. Date of Electronic Publication: 2019 Jul 29.Publisher: Wiley Blackwell Country of Publication: England NLM ID: 101543738 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

×
Academic Journal

Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.

Subjects: Drug Costs* ; Economics, Pharmaceutical*; Cost-Benefit Analysis/Cost-Benefit Analysis/Cost-Benefit Analysis/*methods

  • Source: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2010 Jan-Feb; Vol. 13 (1), pp. 14-7. Date of Electronic Publisher: Elsevier Country of Publication: United States NLM ID: 100883818 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

×
Academic Journal

Rising Drug Costs Drives the Growth of Pharmacy Benefit Managers Exclusion Lists: Are Exclusion Decisions Value-Based?

  • Authors : Cohen JP; Tufts Center for the Study of Drug Development, Boston, MA.; Khoury CE

Subjects: Cost-Benefit Analysis/Cost-Benefit Analysis/Cost-Benefit Analysis/*statistics & numerical data ; Fees, Pharmaceutical/Fees, Pharmaceutical/Fees, Pharmaceutical/*statistics & numerical data ; Prescription Drugs/Prescription Drugs/Prescription Drugs/*economics

  • Source: Health services research [Health Serv Res] 2018 Aug; Vol. 53 Suppl 1, pp. 2758-2769. Date of Electronic Publication: 2017 Oct 18.Publisher: Blackwell Country of Publication: United States NLM ID: 0053006 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

×
Academic Journal

Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.

  • Authors : Kenet G; National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel.; Sackler Medical School, Tel Aviv University, Tel Hashomer, Israel.

Subjects: Cost-Benefit Analysis* ; Drug Costs* ; Immune Tolerance*

  • Source: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2017 Sep; Vol. 23 (5), pp. e394-e402. Date of Electronic Publication: 2017 Jun 22.Publisher: Blackwell Science Country of Publication: England NLM ID: 9442916 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

×
Academic Journal

A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology.

  • Authors : Erku D; Centre for Applied Health Economics, Griffith University, Nathan, Queensland, Australia.; Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia.

Subjects: Cost-Benefit Analysis*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*administration & dosage ; Drug Monitoring/Drug Monitoring/Drug Monitoring/*economics

  • Source: Pharmacology research & perspectives [Pharmacol Res Perspect] 2021 Oct; Vol. 9 (5), pp. e00862.Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States

تفاصيل العنوان

×
  • 1-10 ل  2,024 نتائج ل ""drug costs""